Shares of NeuroSense Therapeutics surged 15.4% to $4.54 on October 5, snapping a five-session slide, after the company disclosed plans to appeal Nasdaq's move to delist its stock for failing to maintain a $35 million minimum market capitalization — a last-ditch maneuver that buys time but doesn't fix the underlying problem. NeuroSense Buys More Time on Nasdaq — But With $231K in Cash and a $14M Market Cap, Is Survival Realistic?
Shares jumped 15.4% to $4.54 on October 5, reversing a five-session decline, after NeuroSense Therapeutics disclosed it will fight Nasdaq's decision to delist its stock — a move that keeps the lights on for now but highlights how close this tiny biotech is to the edge.
The Delisting Clock Is Ticking, and the Company Already Missed Its Deadline. On October 1, Nasdaq's staff notified NeuroSense it had failed to regain compliance with the $35 million minimum market-value rule.
The company was first warned on April 2, 2026, and given 180 days — until September 29 — to fix the gap. It didn't. By filing a timely appeal, NeuroSense temporarily prevents suspension and keeps trading on Nasdaq while a hearings panel reviews its case.
The panel may, at its discretion, grant an exception period of up to 180 additional days, during which the company would need to present a credible plan to raise its market value.
The Math Doesn't Add Up — Yet. As of October 2, NeuroSense's market capitalization stood at roughly $14 million — less than half the $35 million threshold. Closing that gap requires either a dramatic share-price rally or new equity issuance, and both paths are treacherous. The company reported just $231,000 in cash against nearly $3 million in total liabilities as of June 30, triggering a formal going-concern warning — auditor language signaling the firm may not survive the next twelve months. Any dilutive capital raise could push the stock lower, making the market-cap hurdle even harder to clear.
A Reverse Split Fixed One Problem; Science Could Fix the Other. NeuroSense recently regained compliance with Nasdaq's separate $1.00 minimum bid-price rule after executing a 1-for-20 reverse stock split. On the clinical front, the company has real ammunition: its Phase 2b trial of an ALS combination therapy showed a 65% reduction in risk of death and a median survival benefit of 14.3 months versus placebo.
The FDA has cleared a global Phase 3 study , and NeuroSense is targeting a drug-application filing with Health Canada in December 2026. Positive regulatory news could reignite investor interest — if the company survives long enough to deliver it.
Why Today's Rally May Be Misleading. A 15% pop on thin volume in a micro-cap stock is noise, not a verdict. Delisting would materially impair shareholders' ability to trade the stock and could significantly damage the company's ability to raise capital. The appeal buys months, not certainty. Investors are now betting on a race between a cash-starved balance sheet and a promising drug pipeline — with Nasdaq holding the stopwatch.